CD274 and breast cancer: Regarding the combination with ICIs, the KATE2 phase II randomized trial was the first study to evaluate the combination of T-DM1 with atezolizumab, a programmed death ligand-1 (PD-L1), in patients with previously treated HER2-positive metastatic BC.